Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination

Phase 0 Recruiting 45 enrolled University of Florida National Institute on Drug Abuse (NIDA) · collab

RandomizedCrossoverDouble-blindBasic science

Summary

Some research suggests that administration of oxytocin with oxycodone may reduce its abuse liability and improve its ability to reduce pain. In a 6-session laboratory study, the investigators will be evaluating the effects of oxycodone and oxytocin (combined and separately, across sessions) on experimentally-induced pain, subjective effects, decision-making, and activation of different neural substrates.

Timeline

Start: 2021-09-02
Primary completion: 2026-12-31
Completion: 2026-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Oxycodone	Other / unclassified	2.5 mg	Oral
Comparator	Oxycodone	Other / unclassified	5 mg	Oral
Comparator	Oxytocin	Peptide	48 iu	Intranasal

Indications

No indication recorded.